Fung-Kee-Fung M - Search Results

1

A novel, more reliable approach to use of progression-free survival as a predictor of gain in overall survival: The Ottawa PFS Predictive Model.

Stewart DJ, Bossé D, Goss G, Hilton JF, Jonker D, Fung-Kee-Fung M. Stewart DJ, et al. Crit Rev Oncol Hematol. 2020 Apr;148:102896. doi: 10.1016/j.critrevonc.2020.102896. Epub 2020 Feb 8. Crit Rev Oncol Hematol. 2020. PMID: 32087510 Review.

2

Potential insights from population kinetic assessment of progression-free survival curves.

Stewart DJ, Bosse D, Robinson A, Ong M, Fung-Kee-Fung M, Brule S, Hilton JF, Ocana A. Stewart DJ, et al. Crit Rev Oncol Hematol. 2020 Sep;153:103039. doi: 10.1016/j.critrevonc.2020.103039. Epub 2020 Jun 26. Crit Rev Oncol Hematol. 2020. PMID: 32622319 Review.

3

The need for speed in advanced non-small cell lung cancer: A population kinetics assessment.

Stewart DJ, Maziak DE, Moore SM, Brule SY, Gomes M, Sekhon H, Dennie C, Lo B, Fung-Kee-Fung M, Bradford JP, Reaume MN. Stewart DJ, et al. Among authors: fung kee fung m. Cancer Med. 2021 Dec;10(24):9040-9046. doi: 10.1002/cam4.4411. Epub 2021 Nov 11. Cancer Med. 2021. PMID: 34766461 Free PMC article.

4

Cancer Clinic Redesign: Opportunities for Resource Optimization.

Fung-Kee-Fung M, Ozer RS, Davies B, Pick S, Duke K, Stewart DJ, Reaume MN, Ward M, Balchin K, MacRae RM, Nelson S, Renaud J, Garvin D, Madore S, Pantarotto JR. Fung-Kee-Fung M, et al. Curr Oncol. 2022 May 31;29(6):3983-3995. doi: 10.3390/curroncol29060318. Curr Oncol. 2022. PMID: 35735427 Free PMC article.

5

The role of topotecan as second-line therapy in patients with recurrent ovarian cancer.

Beshara N, Fung Kee Fung M, Faught W. Beshara N, et al. Eur J Gynaecol Oncol. 2002;23(4):287-90. Eur J Gynaecol Oncol. 2002. PMID: 12214724

6

Systematic review of systemic therapy for advanced or recurrent endometrial cancer.

Carey MS, Gawlik C, Fung-Kee-Fung M, Chambers A, Oliver T; Cancer Care Ontario Practice Guidelines Initiative Gynecology Cancer Disease Site Group. Carey MS, et al. Gynecol Oncol. 2006 Apr;101(1):158-67. doi: 10.1016/j.ygyno.2005.11.019. Epub 2006 Jan 24. Gynecol Oncol. 2006. PMID: 16434086 Review.

7

Follow-up after primary therapy for endometrial cancer: a systematic review.

Fung-Kee-Fung M, Dodge J, Elit L, Lukka H, Chambers A, Oliver T; Cancer Care Ontario Program in Evidence-based Care Gynecology Cancer Disease Site Group. Fung-Kee-Fung M, et al. Gynecol Oncol. 2006 Jun;101(3):520-9. doi: 10.1016/j.ygyno.2006.02.011. Epub 2006 Mar 23. Gynecol Oncol. 2006. PMID: 16556457 Review.

8

Intraperitoneal chemotherapy for patients with advanced ovarian cancer: a review of the evidence and standards for the delivery of care.

Fung-Kee-Fung M, Provencher D, Rosen B, Hoskins P, Rambout L, Oliver T, Gotlieb W, Covens A; IP Chemotherapy Working Group/Society of Gynecologic Oncologists of Canada. Fung-Kee-Fung M, et al. Gynecol Oncol. 2007 Jun;105(3):747-56. doi: 10.1016/j.ygyno.2007.02.015. Epub 2007 Mar 21. Gynecol Oncol. 2007. PMID: 17368522

9

The lack of significance of Ca125 response in epithelial ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.

Le T, Hopkins L, Faught W, Fung-Kee-Fung M. Le T, et al. Gynecol Oncol. 2007 Jun;105(3):712-5. doi: 10.1016/j.ygyno.2007.02.022. Epub 2007 Apr 2. Gynecol Oncol. 2007. PMID: 17400284

10

Omental chemotherapy effects as a prognostic factor in ovarian cancer patients treated with neoadjuvant chemotherapy and delayed primary surgical debulking.

Le T, Williams K, Senterman M, Hopkins L, Faught W, Fung-Kee-Fung M. Le T, et al. Ann Surg Oncol. 2007 Sep;14(9):2649-53. doi: 10.1245/s10434-007-9460-2. Epub 2007 Jun 12. Ann Surg Oncol. 2007. PMID: 17562112

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

92 results

Search Page